 "Zydus launches affordable diabetic drug Tenglyn")
Zydus claimed that with an aim to make this important therapy affordable and accessible to diabetic patients, Tenglyn is being priced at Rs 7 per tablet which is almost one-sixth the price at which the Gliptins were initially launched in India.
Gliptins have shown promise in achieving glycemic control without deteriorating beta cell function and is one of the most recent advancements in diabetes care and management.
Speaking on the development, Sharvil Patel, deputy managing director, Zydus Cadila, said, "Diabetes, as we know, is becoming a major health burden globally. We remain committed to this fight against diabetes and with Tenglyn we provide patients suffering from diabetes access to this advanced treatment at the most affordable cost."
The number of diabetics in the world is estimated to be over 360 million. With a patient population of almost 65 million diabetics in India, access to affordable therapy is critical.
The group had earlier launched Lipaglyn (Saroglitazar), for the treatment of diabetic dyslipidemia and hypertriglyceridemia. It has over 20 discovery programmes in the areas of diabetes and other cardio-metabolic disorders.
